The role of extracellular matrix in small-cell lung cancer

Lancet Oncology

Volumn 2, Issue 7, 2001, Pages 437-442

  Rintoul, Robert C ^a   Sethi, Tariq ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRIN; MATRIX METALLOPROTEINASE;

DRUG EFFECT; DRUG RESISTANCE; EXTRACELLULAR MATRIX; HUMAN; IMMUNOLOGY; LUNG TUMOR; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SMALL CELL CARCINOMA;

CARCINOMA, SMALL CELL; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR MATRIX; HUMANS; INTEGRINS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASES; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0035411293     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00421-6     Document Type: Review

References (56)

1. WHO. World Health Organisation Mortality Statistics. http://www.who.int/whosis/mort . Accessed in June 2000.
2. Green R.A., Humphrey E., Close H. Alkylating agents in bronchogenic carcinoma. Am J Med. 46:1969;516-525.
3. Elias A.D. Small cell lung cancer: state of the art therapy in 1996. Chest. 112:1997;251S-258S.
4. Sethi T., Rintoul R.C., Moore S.M., et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med. 5:1999;662-668.
5. Schwartz M.A., Schaller M.D., Ginsberg M.H. Integrins: emerging paradigms of signal transduction. Annu Rev Cell Dev Biol. 11:1995;549-599.
6. Jones J.L., Walker R.A. Integrins: a role as cell signalling molecules. Mol Pathol. 52:1999;208-213.
7. Hirasawa M., Shijubo N., Uede T., Abe S. Integrin expression and ability to adhere to extracellular matrix proteins and endothelial cells in human lung cancer lines. Br J Cancer. 70:1994;466-473.
8. Koukoulis G.K., Warren W.H., Virtanen I., Gould V.E. Immunolocalization of integrins in the normal lung and in pulmonary carcinomas. Hum Pathol. 28:1997;1018-1025.
9. Guo N., Templeton N.S., Al-Barazi H., et al. Thrombospondin-1 promotes alpha3beta1 integrin-mediated adhesion and neurite-like outgrowth and inhibits proliferation of small cell lung carcinoma cells. Cancer Res. 15:2000;457-466.
10. Palecek S.P., Loftus J.C., Ginsberg M.H., et al. Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature. 385:1997;537-540.
11. Huttenlocher A., Ginsberg M.H., Horwitz A.F. Modulation of cell migration by integrin-mediated cytoskeletal linkages and ligand-binding affinity. J Cell Biol. 134:1996;1551-1562.
12. Hughes P.E., Pfaff M. Integrin affinity modulation. Trends Cell Biol. 8:1998;359-364.
13. Huncharek M., Muscat J., Geschwind J.F. K-RAS oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis. 20:1999;1507-1510.
14. Moore S.M., Rintoul R.C., Walker T.R., et al. The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway. Cancer Res. 58:1998;5239-5247.
15. Humphries M.J. Integrin activation: the link between ligand binding and signal transduction. Curr Opin Cell Biol. 8:1996;632-640.
16. Fenczik C.A., Sethi T., Ramos J.W., et al. Complementation of dominant suppression implicates CD98 in integrin activation. Nature. 390:1997;81-85.
17. Quigley R.L., Shafer S.H., Williams C.L. Regulation of integrin-mediated adhesion by muscarinic acetylchloine receptors and protein kinase C in small cell lung carcinoma. Chest. 114:1998;839-846.
18. Sheski F.D., Natarajan V., Pottratz S.T. Tumor necrosis factor-alpha stimulates attachment of small cell lung carcinoma to endothelial cells. J Lab Clin Med. 133:1999;265-273.
19. Yamada K.M., Kennedy D.W., Yamada S.S., et al. Monoclonal antibody and synthetic peptide inhibitors of human tumour cell migration. Cancer Res. 50:1990;4485-4496.
20. Sun R., Hojo H., Kato K., Hashimoto Y. Effects of anti-intercellular adhesion molecule-1 and anti-lymphocyte-function-associated antigen-1 monoclonal antibodies on the metastasis of murine tumors. Invasion Metastasis. 16:1996;39-48.
21. Kuijpers T.W., Mul E.P., Blom M., et al. Freezing adhesion molecules in a state of high-avidity binding blocks eosinophil migration. J Exp Med. 178:1993;279-284.
22. Giancotti F.G., Rouslahti E. Elevated levels of the alpha 5 beta 1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell. 60:1990;849-859.
23. Pyke C., Ralfkiaer E., Tryggvason K., Dano K. Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol. 142:1993;359-365.
24. Heppner K.J., Matrisian L.M., Jensen R.A., Rodgers W.H. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol. 149:1996;273-282.
25. Odekon L.E., Sato Y., Rifkin D.B. Urokinase-type plasminogen activator mediates basic growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J Cell Physiol. 150:1992;258-263.
26. Binder B.R. Influence of urokinase on cell proliferation and invasion. Blood Coagul Fibrinolysis. 1:1990;717-720.
27. Pepper M.S., Sappino A.P., Stocklin R., et al. Upregulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol. 122:1993;673-684.
28. Liu G., Shuma M.A., Cohen R.L. Coexpression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer. 60:1995;501-506.
29. Garbisa S., Pozzatti R., Muschel R.J., et al. Secretion of type IV collagenolytic protease and metastatic phenotype: induction of transfection with c-HA-RAS but not c-HA-RAS plus Ad2-Ela. Cancer Res. 47:1997;1523-1528.
30. Talbot D.C., Brown P.D. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer. 32A:1996;2528-2533.
31. Valente P., Fassina G., Melchiori A., et al. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer. 75:1998;246-253.
32. Montgomery A.M., Mueller B.M., Reisfeld R.A., et al. Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res. 54:1994;5467-5473.
33. Khokha R., Denhardt D.T. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: a review of their role in tumourigenesis and tissue invasion. Invasion Metastasis. 9:1989;391-405.
34. Michael M., Babic B., Khokha R., et al. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol. 17:1999;1802-1802.
35. Fidler I.J., Ellis L.M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 79:1994;185-188.
36. Boudreau N., Andrews C., Srebrow A., et al. Induction of the angiogenic phenotype by HOX D3. J Cell Biol. 139:1997;257-264.
37. Friedlander M., Brooks P.C., Shaffer R.W., et al. Definition of two angiogenic pathways by distinct alpha v integrins. Science. 270:1995;1500-1502.
38. O'Reilly M.S., Goehm T., Shing Y., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumour growth. Cell. 88:1997;277-285.
39. Eisen T.G. Thalidomide in solid tumours: the London experience. Oncology. 12:2000;17-20.
40. Pommier Y., Kerrigan D., Schwartz R.E., et al. Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res. 46:1986;3075-3081.
41. Danks M.K., Schmidt C.A., Cirtain M.C., et al. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry. 27:1988;8861-8869.
42. De Jong S., Zijlstra J.G., de Vries E.G., Mulder N.H. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res. 50:1990;304-309.
43. Borst P., Schinkel A.H., Smit J.J., et al. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol Ther. 60:1993;289-299.
44. Cole S.P., Bhardwaj G., Gerlach J.H., et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 258:1992;1650-1654.
45. Narasaki F., Matsuo I., Ikuno N., et al. Multidrug resistance-associated protein (MRP) gene expression in human lung cancer. Anticancer Res. 16:1996;2079-2082.
46. Nooter K., Bosman F.T., Burger H., et al. Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer. Ann Oncol. 7:1996;75-81.
47. Hannun Y.A. Apoptosis and the dilemma of cancer chemotherapy. Blood. 89:1997;1845-1853.
48. Frisch S.M., Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 124:1994;619-626.
49. Boudreau N., Sympson C., Werb Z., Bissell M. Suppresion of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science. 267:1995;891-893.
50. Hoyt D.G., Rusnak J.M., Mannix R.J., et al. Integrin activation suppresses etoposide-induced DNA strand breakage in cultured murine tumor-derived endothelial cells. Cancer Res. 56:1996;4146-4149.
51. Kreisholt J., Sorensen M., Jensen P.B., et al. Immunohistochemical detection of DNA topoisomerase II alpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer. Br J Cancer. 77:1998;1469-1473.
52. Macaulay V.M., Everard M.J., Teale J.D., et al. Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells. Cancer Res. 50:1990;2511-2517.
53. Sethi T., Rozengurt E. Multiple neuropeptides stimulate clonal growth of small cell lung cancer: effects of bradykinin, vasopressin, cholecystokinin, galanin, and neurotensin. Cancer Res. 51:1991;3621-3623.
54. Fischer J.R., Darjes H., Lahm H., et al. Constitutive secretion of bioactive transforming growth factor beta 1 by small cell lung cancer cell lines. Eur J Cancer. 30A:1994;2125-2129.
55. Arenberg D.A., Kunkel S.L., Polverini P.J., et al. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest. 97:1996;2792-2792.
56. Tsai C.M., Levitzki A., Wu L.H., et al. Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells. Cancer Res. 56:1996;1068-1074.